A judge’s gavel falls on a high profile case stemming from the death of a well-known actor in 2023. Jasveen Sangha, known in certain circles as the “Ketamine Queen,” now faces decades in federal prison after agreeing to plead guilty to five charges in Los Angeles.
Plea Deal and Charges The 42-year-old American-British dual citizen has admitted to distributing ketamine that resulted in death or serious injury, under a plea agreement with prosecutors. She originally faced nine counts, and investigators described a location linked to her operations as a “drug-selling emporium” after locating dozens of ketamine vials during a raid.
Cause of death The actor was found dead in his home’s jacuzzi in October 2023. An autopsy determined that acute ketamine intoxication contributed to his death.
Five accused in the supply chain Sangha is among five individuals charged in connection with the actor’s drug supply. Prosecutors allege the group exploited the actor’s ongoing struggles with addiction for financial gain. The other accused include two physicians accused of selling ketamine directly to the actor, the actor’s live-in assistant who allegedly helped purchase and even administered the drug, and a fourth person who bought ketamine from Sangha and resold it.
Court proceedings All five defendants have now agreed to plead guilty. Sangha’s trial had faced several delays and was scheduled to begin next month, but the plea agreement ends that timeline. She is expected to appear in federal court soon to formally enter her guilty plea as part of the deal.
Her attorney said she is taking responsibility for her actions. Sangha will plead guilty to operating a drug related premises, three counts of distributing ketamine, and one count of distributing ketamine that caused death or serious injury. Federal prosecutors note a maximum sentence of up to 65 years in prison if convicted on all counts.


 
             
                                     
                                     
                                     
                             
                            

 
                                     
                                     
                                     
                                    
+ There are no comments
Add yours